NICE Guidance on Fedratinib for the treatment of Myelofibrosis

We are delighted to announce that NICE (the National Institute for Health and Care Excellence) has recently released guidance recommending fedratinib as an option within the NHS for treating disease-related splenomegaly (enlarged spleen) or symptoms of myelofibrosis in adult patients who have previously been treated with ruxolitinib and for whom momelotinib is unsuitable. This positive news follows a detailed appraisal…

In Conversation with… Prof Claire Harrison regarding the temporary shortage of Interferon

In conversation with Prof Claire Harrison, Guy’s & St Thomas’ NHS FT, who clarifies the situation regarding the temporary shortage of Interferon, which is due to the manufacturing rights of Interferon transferring from Hoffmann-La Roche to Pharma& and the commissioning of a new manufacturing plant.  Prof Harrison stresses that the current shortage is temporary and…

Update on review of Besremi for the treatment of PV in Ireland

The NCPE, the body that assesses and recommends drugs for use by the health services in Ireland, has recently released initial advice following their assessment of ropeginterferon alfa-2b (Besremi) for the treatment of patients with Polycythaemia Vera. As part of that assessment process MPN Voice made a patient group submission highlighting the benefits of Besremi…

Calling All Young MPN Patients!

Were you diagnosed with an MPN (Myeloproliferative Neoplasm) before the age of 40?  We want to hear from YOU! Your experiences are invaluable in helping us improve our resources and support for young MPN patients. Please share your thoughts on our latest leaflet – read here – and take just 2 minutes to complete our…